---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016445"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:29:16.677941+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protalix repays all convertible notes, becomes debt-free; EMA validates Fabry drug dosing variation

## Summary
- Repaid in full all outstanding convertible notes, making company debt-free.
- EMA validated Chiesi's variation submission for pegunigalsidase alfa every-four-week dosing in EU.
- Completed Phase I trial of PRX-115 for uncontrolled gout; Phase II planned H2 2025.
- Revenue streams from Elfabrio, Elelyso, and Uplyso growing; full operations maintained despite Israel conflict.
- Fine-tuned R&D strategy on renal rare diseases and plant-based drug delivery.

## SEC filing metadata
- accession: 0001558370-24-016445
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024016445/0001558370-24-016445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024016445/plx-20241223x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016445
- JSON: https://secwatch.observer/filing/0001558370-24-016445.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.